Novartis' star gene therapy faces potential safety issue following a recent infant death in study
Novartis got some more upbeat press earlier in the week when researchers on the Zolgensma gene therapy program outlined some updated biomarker data on their SMA drug and noted that 21 of 22 patients were alive and event free as of last fall. But it turns out there was a post script to the study that raises some safety concerns for the pharma giant’s therapy — recently acquired in an $8.7 billion acquisition of AveXis.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.